We recently found that the Arf1‐mediated lipid metabolism selectively sustains cancer cells (particularly stem cells) and knockdown of the pathway not only kills cancer cells but also elicits a tumor‐specific immune response that converts dying cancer cells into a therapeutic vaccine, which both significantly increases tumor‐infiltrating and activation of DCs and CD8+ T cells.[27, 28] However, the relationship among tumor cells, DCs, and T cells in activating anti‐tumor immunity in the Arf1‐ablated tumor microenvironment remains unknown. This evidence concerns the gene ARF1 and cancer.